Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $904.62 billion. The enterprise value is $936.96 billion.
| Market Cap | 904.62B |
| Enterprise Value | 936.96B |
Important Dates
The last earnings date was Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Nov 14, 2025 |
Share Statistics
Eli Lilly has 895.38 million shares outstanding. The number of shares has decreased by -0.41% in one year.
| Current Share Class | 895.38M |
| Shares Outstanding | 895.38M |
| Shares Change (YoY) | -0.41% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 87.25% |
| Float | 893.13M |
Valuation Ratios
The trailing PE ratio is 49.42 and the forward PE ratio is 32.46. Eli Lilly's PEG ratio is 1.05.
| PE Ratio | 49.42 |
| Forward PE | 32.46 |
| PS Ratio | 15.27 |
| Forward PS | 12.29 |
| PB Ratio | 38.04 |
| P/TBV Ratio | 79.02 |
| P/FCF Ratio | 97.57 |
| P/OCF Ratio | 56.32 |
| PEG Ratio | 1.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.61, with an EV/FCF ratio of 101.05.
| EV / Earnings | 50.89 |
| EV / Sales | 15.77 |
| EV / EBITDA | 32.61 |
| EV / EBIT | 34.92 |
| EV / FCF | 101.05 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.79.
| Current Ratio | 1.55 |
| Quick Ratio | 0.72 |
| Debt / Equity | 1.79 |
| Debt / EBITDA | 1.47 |
| Debt / FCF | 4.59 |
| Interest Coverage | 29.91 |
Financial Efficiency
Return on equity (ROE) is 96.47% and return on invested capital (ROIC) is 29.95%.
| Return on Equity (ROE) | 96.47% |
| Return on Assets (ROA) | 17.60% |
| Return on Invested Capital (ROIC) | 29.95% |
| Return on Capital Employed (ROCE) | 35.87% |
| Revenue Per Employee | $1.26M |
| Profits Per Employee | $391,747 |
| Employee Count | 47,000 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.03 |
Taxes
In the past 12 months, Eli Lilly has paid $4.09 billion in taxes.
| Income Tax | 4.09B |
| Effective Tax Rate | 18.18% |
Stock Price Statistics
The stock price has increased by +21.75% in the last 52 weeks. The beta is 0.37, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +21.75% |
| 50-Day Moving Average | 911.53 |
| 200-Day Moving Average | 811.94 |
| Relative Strength Index (RSI) | 54.01 |
| Average Volume (20 Days) | 3,887,839 |
Short Selling Information
The latest short interest is 7.25 million, so 0.81% of the outstanding shares have been sold short.
| Short Interest | 7.25M |
| Short Previous Month | 6.84M |
| Short % of Shares Out | 0.81% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 1.85 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $59.42 billion and earned $18.41 billion in profits. Earnings per share was $20.44.
| Revenue | 59.42B |
| Gross Profit | 49.34B |
| Operating Income | 26.83B |
| Pretax Income | 22.50B |
| Net Income | 18.41B |
| EBITDA | 28.73B |
| EBIT | 26.83B |
| Earnings Per Share (EPS) | $20.44 |
Balance Sheet
The company has $9.91 billion in cash and $42.58 billion in debt, giving a net cash position of -$32.34 billion or -$36.12 per share.
| Cash & Cash Equivalents | 9.91B |
| Total Debt | 42.58B |
| Net Cash | -32.34B |
| Net Cash Per Share | -$36.12 |
| Equity (Book Value) | 23.85B |
| Book Value Per Share | 26.56 |
| Working Capital | 21.93B |
Cash Flow
In the last 12 months, operating cash flow was $16.06 billion and capital expenditures -$6.79 billion, giving a free cash flow of $9.27 billion.
| Operating Cash Flow | 16.06B |
| Capital Expenditures | -6.79B |
| Free Cash Flow | 9.27B |
| FCF Per Share | $10.36 |
Margins
Gross margin is 83.03%, with operating and profit margins of 45.16% and 30.99%.
| Gross Margin | 83.03% |
| Operating Margin | 45.16% |
| Pretax Margin | 37.87% |
| Profit Margin | 30.99% |
| EBITDA Margin | 48.35% |
| EBIT Margin | 45.16% |
| FCF Margin | 15.60% |
Dividends & Yields
This stock pays an annual dividend of $6.00, which amounts to a dividend yield of 0.59%.
| Dividend Per Share | $6.00 |
| Dividend Yield | 0.59% |
| Dividend Growth (YoY) | 15.38% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 29.35% |
| Buyback Yield | 0.41% |
| Shareholder Yield | 1.01% |
| Earnings Yield | 2.04% |
| FCF Yield | 1.02% |
Analyst Forecast
The average price target for Eli Lilly is $1,063.44, which is 5.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1,063.44 |
| Price Target Difference | 5.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 16.99% |
| EPS Growth Forecast (5Y) | 29.83% |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 6.49 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 6 |